Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 44.9% in February

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 83,000 shares, a growth of 44.9% from the February 13th total of 57,300 shares. Approximately 11.1% of the company’s shares are short sold. Based on an average daily volume of 318,400 shares, the short-interest ratio is currently 0.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating and issued a $350.00 price objective on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

Windtree Therapeutics Trading Down 0.5 %

Shares of NASDAQ WINT opened at $2.05 on Monday. The firm has a market capitalization of $1.54 million, a PE ratio of -0.12 and a beta of 0.68. The firm’s 50-day moving average is $6.99 and its 200-day moving average is $47.92. Windtree Therapeutics has a 1 year low of $1.78 and a 1 year high of $737.44.

Institutional Trading of Windtree Therapeutics

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC purchased a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics at the end of the most recent reporting period. 29.33% of the stock is currently owned by institutional investors.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.